# Alba Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alba-therapeutics

- Industry: Biotechnology
- Headquarters: Baltimore, US
- Website: www.albatherapeutics.com
- Total disclosed funding: $30M
- Latest round: Series A (Aug 24, 2005)
- Investors on record: 5

## About

Alba Therapeutics is a biotechnology firm specializing in innovative therapies for gastrointestinal diseases, particularly celiac disease, through their proprietary glutenase enzyme formulation.Founded in 2004 and headquartered in Baltimore, US, Alba Therapeutics develops treatments targeting autoimmune disorders related to the gastrointestinal tract. The company has successfully completed three deals, with its most recent funding in November 2006, where it raised USD 10 mn in VENTURE DEBT from ATEL Capital Group, Oxford Finance Corporation, and Silicon Valley Bank, bringing the total amount raised to USD 30 mn. Alba Therapeutics was established to address unmet needs in gastrointestinal health.Alba Therapeutics focuses on developing innovative therapies aimed at treating diseases related to the gastrointestinal tract, with an emphasis on conditions such as celiac disease and other autoimmune disorders. Their primary product, a proprietary formulation of a glutenase enzyme, aims to mitigate the effects of gluten consumption in individuals with celiac disease by breaking down gluten proteins, thus providing relief from gastrointestinal symptoms. This product was specifically designed for patients who are sensitive to gluten and require alternative management options beyond strict dietary restrictions. The company targets healthcare providers, gastroenterologists, and patients within the United States and selected international markets, including Europe and Canada. By providing a therapeutic solution, Alba Therapeutics aims to enhance the quality of life for individuals burdened by gluten-related disorders.Alba Therapeutics generates revenue primarily through direct sales of their flagship therapy and potential partnerships with healthcare providers and institutions. The company structures transactions based on a B2B model, where healthcare providers may purchase the glutenase enzyme through established distribution channels. Pricing structures, while not publicly detailed, vary based on the volume of purchase and contractual agreements with healthcare facilities. The company also explores collaborations that may involve licensing agreements or co-development partnerships for further product development. By leveraging relationships with healthcare professionals, Alba Therapeutics positions its products to be integrated into treatment regimens for patients with gluten sensitivities, ultimately fueling their revenue through the uptake of these therapeutic solutions.Alba Therapeutics plans to utilize the recent USD 10 mn in VENTURE DEBT financing to support the development of new products, focusing on expanding their glutenase enzyme therapy and exploring additional therapeutic areas related to gastrointestinal health. The company is targeting expansion into international markets, with a focus on Europe and Canada, aiming to establish a presence by the end of 2024. Their strategy includes increasing collaboration with healthcare providers to enhance product accessibility and integration.

## Funding rounds

- Series A, Aug 24, 2005, $30M — Alta Partners, HealthCap, Maryland Venture Capital Trust, SV Health Investors, Red Abbey

## Investors

- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series A
- HealthCap — Series A
- Maryland Venture Capital Trust (https://capitalatlas.ai/funds/maryland-venture-capital-trust) — Series A
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series A
- Red Abbey (https://capitalatlas.ai/funds/red-abbey) — Series A